AdAlta Limited (ASX:1AD) Reports Q3 FY25 Progress on Immunotherapy Strategy
AdAlta Limited (ASX:1AD) reports significant advancements in its cellular immunotherapy strategy and outlines financial updates for Q3 FY25.
Category: ASX-1AD
AdAlta Limited
Latest News
Ark Mines Ltd (ASX:AHK) Secures $1.5M Through Share Placement
Clean TeQ Water Limited (ASX:CNQ) Secures A$1.2M Contract for DESALX® Project
Pantoro Gold Limited (ASX:PNR) to Clear Debt After Repayment of Convertible Loan
BluGlass (ASX:BLG) Completes $2.3M Placement and Launches $6M SPP Offer
ONCOSIL MEDICAL LTD (ASX:OSL) Announces Security Consolidation
Perpetual Resources Limited (ASX:PEC) Announces Maiden Lithium Drilling Campaign
Wide Open Agriculture Limited (ASX:WOA) Clarifies Offtake and Distribution Agreement
Platinum Asset Management Limited (ASX:PTM) Discusses Potential Merger with L1 Capital
Imricor Medical Systems (ASX:IMR) Announces First Real-time MRI-guided Ablations at Semmelweis University
Blackstone Minerals (ASX:BSX) Confirms High-Grade Copper-Gold Core at Mankayan
The Hub of Australian Finance News